• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型口服活性铁螯合剂ICL670A在人肝细胞培养物中比O-三烯胺表现出更高的抗增殖作用。

The new orally active iron chelator ICL670A exhibits a higher antiproliferative effect in human hepatocyte cultures than O-trensox.

作者信息

Chantrel-Groussard Karine, Gaboriau François, Pasdeloup Nicole, Havouis René, Nick Hanspeter, Pierre Jean-Louis, Brissot Pierre, Lescoat Gérard

机构信息

Inserm, U522, Rennes, France.

出版信息

Eur J Pharmacol. 2006 Jul 17;541(3):129-37. doi: 10.1016/j.ejphar.2006.05.001. Epub 2006 May 11.

DOI:10.1016/j.ejphar.2006.05.001
PMID:16765341
Abstract

By comparing the antiproliferative effect of the iron chelators ICL670A and O-trensox in the human hepatoma cell line HUH7 and human hepatocyte cultures, we have shown that ICL670A decreased cell viability, inhibited DNA replication and induced DNA fragmentation more efficiently than O-trensox. O-trensox and ICL670A induced a cell cycle blockade in G0-G1 and S phases respectively. In parallel, ICL670A inhibited polyamine biosynthesis by decreasing ornithine decarboxylase and spermidine/spermine N(1)-acetyltransferase activities. O-trensox increased polyamine biosynthesis and particularly putrescine level by stimulating spermidine-spermine N(1)-acetyltransferase activity which could activate the polyamine retro-conversion pathway. Moreover, the two chelators exhibit some cytotoxic effect in the two culture models; ICL670A was more cytotoxic than O-trensox and higher concentrations of the two chelators were necessary to induce a cytotoxicity in primary cultures versus hepatoma cells. These results suggested that ICL670A has the most efficient antitumoral effect, blocks cell proliferation by a pathway different of O-trensox and may constitute a potential drug for anticancer therapy.

摘要

通过比较铁螯合剂ICL670A和O - trensox在人肝癌细胞系HUH7和人肝细胞培养物中的抗增殖作用,我们发现ICL670A比O - trensox更有效地降低细胞活力、抑制DNA复制并诱导DNA片段化。O - trensox和ICL670A分别在G0 - G1期和S期诱导细胞周期阻滞。同时,ICL670A通过降低鸟氨酸脱羧酶和亚精胺/精胺N(1)-乙酰转移酶活性来抑制多胺生物合成。O - trensox通过刺激亚精胺 - 精胺N(1)-乙酰转移酶活性来增加多胺生物合成,特别是腐胺水平,这可能激活多胺逆向转化途径。此外,这两种螯合剂在两种培养模型中均表现出一定的细胞毒性;ICL670A比O - trensox的细胞毒性更大,并且与肝癌细胞相比,在原代培养中诱导细胞毒性需要更高浓度的这两种螯合剂。这些结果表明,ICL670A具有最有效的抗肿瘤作用,通过与O - trensox不同的途径阻断细胞增殖,可能构成一种潜在的抗癌治疗药物。

相似文献

1
The new orally active iron chelator ICL670A exhibits a higher antiproliferative effect in human hepatocyte cultures than O-trensox.新型口服活性铁螯合剂ICL670A在人肝细胞培养物中比O-三烯胺表现出更高的抗增殖作用。
Eur J Pharmacol. 2006 Jul 17;541(3):129-37. doi: 10.1016/j.ejphar.2006.05.001. Epub 2006 May 11.
2
Modulation of cell proliferation and polyamine metabolism in rat liver cell cultures by the iron chelator O-trensox.铁螯合剂O-三烯丙基胺对大鼠肝细胞培养物中细胞增殖和多胺代谢的调节作用。
Biometals. 2006 Dec;19(6):623-32. doi: 10.1007/s10534-006-6888-y. Epub 2006 Aug 31.
3
Antiproliferative and iron chelating efficiency of the new bis-8-hydroxyquinoline benzylamine chelator S1 in hepatocyte cultures.新型双-8-羟基喹啉苄胺配体 S1 在肝细胞培养物中的抗增殖和铁螯合效率。
Chem Biol Interact. 2012 Jan 25;195(2):165-72. doi: 10.1016/j.cbi.2011.12.003. Epub 2011 Dec 13.
4
Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism.与CP20相比,口服活性铁螯合剂ICL670在大鼠和人肝癌细胞培养物中的抗增殖和凋亡作用:与多胺代谢的可能关系。
Cell Prolif. 2007 Oct;40(5):755-67. doi: 10.1111/j.1365-2184.2007.00468.x.
5
Antiproliferative and apoptotic effects of O-Trensox, a new synthetic iron chelator, on differentiated human hepatoma cell lines.新型合成铁螯合剂O-Trensox对分化型人肝癌细胞系的抗增殖和凋亡作用
Carcinogenesis. 2000 May;21(5):943-51. doi: 10.1093/carcin/21.5.943.
6
Iron mobilisation and cellular protection by a new synthetic chelator O-Trensox.新型合成螯合剂O-Trensox对铁的动员及细胞保护作用
Biochem Pharmacol. 1998 Jun 1;55(11):1797-806. doi: 10.1016/s0006-2952(98)00009-4.
7
Iron mobilization, cytoprotection, and inhibition of cell proliferation in normal and transformed rat hepatocyte cultures by the hydroxypyridinone CP411, compared to CP20: a biological and physicochemical study.与CP20相比,羟基吡啶酮CP411在正常和转化大鼠肝细胞培养物中的铁动员、细胞保护及细胞增殖抑制作用:一项生物学和物理化学研究
Biochem Pharmacol. 2004 Apr 15;67(8):1479-87. doi: 10.1016/j.bcp.2003.12.019.
8
Chemically induced oxidative stress increases polyamine levels by activating the transcription of ornithine decarboxylase and spermidine/spermine-N1-acetyltransferase in human hepatoma HUH7 cells.化学诱导的氧化应激通过激活人肝癌 HUH7 细胞中鸟氨酸脱羧酶和精脒/精胺-N1-乙酰转移酶的转录来增加多胺水平。
Biochimie. 2012 Sep;94(9):1876-83. doi: 10.1016/j.biochi.2012.04.023. Epub 2012 May 8.
9
Effects of deferasirox and deferiprone on cellular iron load in the human hepatoma cell line HepaRG.地拉罗司和去铁酮对人肝癌细胞系 HepaRG 细胞内铁负荷的影响。
Biometals. 2010 Apr;23(2):231-45. doi: 10.1007/s10534-009-9281-9. Epub 2009 Dec 8.
10
Modulation of cell proliferation in rat liver cell cultures by new calix[4]arenes.新型杯[4]芳烃对大鼠肝细胞培养物中细胞增殖的调节作用。
J Enzyme Inhib Med Chem. 2006 Jun;21(3):261-70. doi: 10.1080/14756360600700384.

引用本文的文献

1
Deferasirox's Anti-Chemoresistance and Anti-Metastatic Effect on Non-Small Cell Lung Carcinoma.地拉罗司对非小细胞肺癌的抗化疗耐药及抗转移作用
Biomedicines. 2024 Oct 7;12(10):2272. doi: 10.3390/biomedicines12102272.
2
A DFX-based iron nanochelator for cancer therapy.一种用于癌症治疗的基于去铁胺的铁纳米螯合剂。
Front Bioeng Biotechnol. 2022 Nov 28;10:1078137. doi: 10.3389/fbioe.2022.1078137. eCollection 2022.
3
Iron Overload and Breast Cancer: Iron Chelation as a Potential Therapeutic Approach.铁过载与乳腺癌:铁螯合作为一种潜在的治疗方法
Life (Basel). 2022 Jun 27;12(7):963. doi: 10.3390/life12070963.
4
Iron-Sulfur Cluster Biogenesis as a Critical Target in Cancer.铁硫簇生物合成作为癌症的关键靶点
Antioxidants (Basel). 2021 Sep 14;10(9):1458. doi: 10.3390/antiox10091458.
5
Iron and Copper Intracellular Chelation as an Anticancer Drug Strategy.铁和铜细胞内螯合作为一种抗癌药物策略
Inorganics (Basel). 2018;6(4). doi: 10.3390/inorganics6040126. Epub 2018 Nov 30.
6
Coupling of the polyamine and iron metabolism pathways in the regulation of proliferation: Mechanistic links to alterations in key polyamine biosynthetic and catabolic enzymes.多胺和铁代谢途径在细胞增殖调控中的偶联:对关键多胺生物合成和分解代谢酶改变的机制联系。
Biochim Biophys Acta Mol Basis Dis. 2018 Sep;1864(9 Pt B):2793-2813. doi: 10.1016/j.bbadis.2018.05.007. Epub 2018 May 16.
7
Expanding the Therapeutic Potential of the Iron Chelator Deferasirox in the Development of Aqueous Stable Ti(IV) Anticancer Complexes.拓展去铁酮在开发水相稳定 Ti(IV)抗癌配合物方面的治疗潜力。
Inorg Chem. 2017 Jul 17;56(14):7788-7802. doi: 10.1021/acs.inorgchem.7b00542. Epub 2017 Jun 23.
8
Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma.口服铁螯合剂地拉罗司对晚期肝细胞癌的影响。
World J Gastroenterol. 2016 Oct 28;22(40):8967-8977. doi: 10.3748/wjg.v22.i40.8967.
9
Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib.地拉罗司,一种口服铁螯合剂,可预防肝癌发生及索拉非尼的不良反应。
J Clin Biochem Nutr. 2016 May;58(3):202-9. doi: 10.3164/jcbn.15-127. Epub 2016 Mar 15.
10
Low oxygen tension reverses antineoplastic effect of iron chelator deferasirox in human glioblastoma cells.低氧张力可逆转铁螯合剂地拉罗司对人胶质母细胞瘤细胞的抗肿瘤作用。
BMC Cancer. 2016 Feb 1;16:51. doi: 10.1186/s12885-016-2074-y.